PAVmed Inc. (PAVM): Price and Financial Metrics

PAVmed Inc. (PAVM): $2.14

0.59 (-21.61%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

PAVM Price/Volume Stats

Current price $2.14 52-week high $9.36
Prev. close $2.73 52-week low $1.60
Day low $2.14 Volume 193,200
Day high $2.66 Avg. volume 72,690
50-day MA $2.26 Dividend yield N/A
200-day MA $4.02 Market Cap 19.63M

PAVM Stock Price Chart Interactive Chart >

PAVM Stock Summary

  • PAVM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.26% of US stocks.
  • Revenue growth over the past 12 months for PAVMED INC comes in at 168.14%, a number that bests 96.97% of the US stocks we're tracking.
  • The volatility of PAVMED INC's share price is greater than that of 99.48% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PAVMED INC are CSTL, JAMF, DOMO, SILK, and DIBS.
  • PAVM's SEC filings can be seen here. And to visit PAVMED INC's official web site, go to www.pavmed.com.

PAVM Valuation Summary

  • In comparison to the median Healthcare stock, PAVM's EV/EBIT ratio is 105.48% lower, now standing at -0.8.
  • Over the past 90 months, PAVM's price/earnings ratio has gone up 96.9.

Below are key valuation metrics over time for PAVM.

Stock Date P/S P/B P/E EV/EBIT
PAVM 2023-12-29 21.9 -0.8 -0.5 -0.8
PAVM 2023-12-28 21.7 -0.8 -0.5 -0.8
PAVM 2023-12-27 21.8 -0.8 -0.5 -0.8
PAVM 2023-12-26 21.8 -0.8 -0.5 -0.8
PAVM 2023-12-22 21.1 -0.7 -0.4 -0.8
PAVM 2023-12-21 20.3 -0.7 -0.4 -0.8

PAVM Growth Metrics

    Its year over year cash and equivalents growth rate is now at 33.35%.
  • Its 3 year net cashflow from operations growth rate is now at -317.74%.
  • Its year over year net income to common stockholders growth rate is now at -96.67%.
PAVM's revenue has moved up $565,000 over the prior 33 months.

The table below shows PAVM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.565 -70.939 -86.017
2022-06-30 0.689 -59.616 -72.114
2022-03-31 0.689 -43.686 -58.064
2021-12-31 0.5 -40.591 -50.63
2021-09-30 0.2 -30.542 -42.157
2021-06-30 0 -28.364 -35.42

PAVM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PAVM has a Quality Grade of D, ranking ahead of 12.56% of graded US stocks.
  • PAVM's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
  • BBLG, SNN, and EYE are the stocks whose asset turnover ratios are most correlated with PAVM.

The table below shows PAVM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 21.356
2021-03-31 0 NA 13.527
2020-12-31 0 NA 10.749
2020-09-30 0 NA 9.995
2020-06-30 0 NA 9.541
2020-03-31 0 NA 9.891

PAVM Price Target

For more insight on analysts targets of PAVM, see our PAVM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.08 Average Broker Recommendation 1.5 (Moderate Buy)

PAVmed Inc. (PAVM) Company Bio


PAVmed Inc. operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.


PAVM Latest News Stream


Event/Time News Detail
Loading, please wait...

PAVM Latest Social Stream


Loading social stream, please wait...

View Full PAVM Social Stream

Latest PAVM News From Around the Web

Below are the latest news stories about PAVMED INC that investors may wish to consider to help them evaluate PAVM as an investment opportunity.

The 3 Most Undervalued Penny Stocks to Buy in December

When economies are set to boom, undervalued penny stocks typically lead the way when it comes to equity rallies.

Gabriel Osorio-Mazzilli on InvestorPlace | December 17, 2023

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—

Yahoo | December 12, 2023

PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today provided additional details on the previously announced dividend of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) for PAVmed shareholders.

Yahoo | December 11, 2023

Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential

There are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change.

Josh Enomoto on InvestorPlace | December 5, 2023

PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors today announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), which equals the number of shares PAVmed will receive in the contemporaneous partial settlement of outstanding intercompany debt owed to PAVmed by Lucid.

Yahoo | December 4, 2023

Read More 'PAVM' Stories Here

PAVM Price Returns

1-mo -28.19%
3-mo -48.06%
6-mo -51.57%
1-year -62.39%
3-year -96.92%
5-year -87.03%
YTD -48.06%
2023 -42.78%
2022 -80.49%
2021 16.04%
2020 76.67%
2019 24.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!